Neurocrine CMO Eiry Roberts to retire in 2025; search underway

NEUROCRINE BIOSCIENCES INC

Chief Medical Officer Eiry W. Roberts, M.D., notified Neurocrine of her plan to retire in 2025 for personal reasons.
Dr. Roberts will remain as CMO until her replacement is on-boarded; the company has initiated a search.
Her retirement is not due to any disagreement with Neurocrine's operations, policies, or practices.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Eiry W. Roberts

Chief Medical Officer

NBIX · NEUROCRINE BIOSCIENCES INC

Filed: July 13, 2023, 7:59 PM ET

On July 10, 2023, Eiry W. Roberts, M.D., notified Neurocrine Biosciences, Inc. (the “Company”) of her decision to retire in 2025 from her position as Chief Medical Officer of the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Eiry W. Roberts retired as Chief Medical Officer at NEUROCRINE BIOSCIENCES INC.

Action: retired
Role: Chief Medical Officer

Exact text from the filing

On July 10, 2023, Eiry W. Roberts, M.D., notified Neurocrine Biosciences, Inc. (the “Company”) of her decision to retire in 2025 from her position as Chief Medical Officer of the Company.

View on SEC.gov

NEUROCRINE BIOSCIENCES INC filing history →

Source: SEC EDGAR

accession 0000914475-23-000049

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.